Skip to Content


In the US, IMBRUVICA (ibrutinib systemic) is a member of the drug class multikinase inhibitors and is used to treat Chronic Lymphocytic Leukemia, Graft-versus-host disease, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma and Waldenström Macroglobulinemia.

US matches:

UK matches:

Ingredient matches for IMBRUVICA


Ibrutinib is reported as an ingredient of IMBRUVICA in the following countries:

  • Croatia (Hrvatska)
  • France
  • Germany
  • Ireland
  • Israel
  • Poland
  • Slovakia
  • Slovenia
  • Switzerland
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.